Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02569632
Other study ID # ChildrensHRCOakland
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date January 2015
Est. completion date December 2016

Study information

Verified date February 2021
Source UCSF Benioff Children's Hospital Oakland
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will investigate the breadth of protection against meningococcal disease in humans immunized with a newly FDA approved meningococcal B vaccine, trade name "Trumenba®" manufactured by Pfizer Vaccines. As a secondary goal the investigators will investigate underlying mechanisms by which human anti-FHbp antibodies elicit complement-mediated bactericidal activity.


Description:

Neisseria meningitidis causes meningitis and severe infections of the blood stream. The incidence of serogroup B meningococcal disease however is too low to conduct a randomized, controlled trial to determine the actual efficacy of the new serogroup B vaccines. Instead vaccine efficacy was inferred from serum bactericidal antibody responses using four test strains. However, because of strain variability of FHbp amino acid sequence (there are more than 800 sequence variants described) and strain variability of FHbp expression, bactericidal data on only four strains are unlikely to be sufficient to predict the actual strain coverage by the vaccine. There also are gaps in knowledge about the underlying mechanisms by which human antibodies to FHbp elicit complement mediated bactericidal activity. For example, binding of FH to FHbp is specific for human FH. Therefore in vaccinated humans the vaccine antigen is expected to form a complex with FH right after immunization. The investigators' hypothesis is that binding of human FH to the vaccine antigen skews the antibody repertoire to FHbp epitopes located outside of the FH combining site. The resulting antibodies would be expected not to inhibit binding of FH to the bacteria. This hypothesis will be investigated in Trumenba-immunized humans as part of studies in Aim 1 (and in future studies of recombinant human anti-FHbp Fabs that will be enabled by obtaining DNA from individual B cells, described in Aim 2).


Recruitment information / eligibility

Status Completed
Enrollment 18
Est. completion date December 2016
Est. primary completion date December 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Adults in the following risk groups: physicians, nurses, respiratory therapists, microbiology laboratory personnel working at UCSF Benioff Children's Hospital Oakland or the University of Massachusetts Medical School as well as medical students attending accredited U.S. medical schools - Able to comprehend and follow all required study procedures - In good health as determined by a brief medical history - For females of child bearing age a negative urine pregnancy test will be required Exclusion Criteria: - Are not in the risk groups summarized above - Have not given or are unable to give written informed consent to participate in the study - Females of child bearing potential who are pregnant, or planning on becoming pregnant during the study period. - Persons with a past history of having Guillain-Barré Syndrome (GBS), or a family history of GBS in a parent or sibling. - Persons with presence or suspected presence of serious chronic disease including but not limited to: chronic cardiac disease, autoimmune disease, diabetes, hepatitis B/C, HIV, progressive neurological disease or seizure, leukemia, lymphomas, or neoplasm. - Have participated in any other investigational drug or received any other vaccine within the last 30 days. - Received a dose of a meningococcal serogroups A, C, Y, W conjugate vaccine within the previous 30 days or wish to receive a dose of this vaccine during the six month study period. - Have a history of anaphylactic shock, asthma, urticaria or other allergic reaction after previous dose of Trumenba - Have experienced fever (oral temperature above 38.0°C) within the past 3 days or are suffering from a present acute infectious disease - Are planning to leave the area of the study site before the end of the study period - Have obesity (BMI higher than 33); or 11. - With any condition which, in the opinion of the investigator, might interfere with the evaluation of the study objectives.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Trumenba Vaccine (Wyeth/Pfizer Pharmaceuticals)
All subjects will receive three doses of a Trumenba, a U.S.-licensed meningococcal vaccine. Each 0.5 mL dose contains 60 micrograms of each FHbp variant (total of 120 micrograms of protein), 0.018 mg of PS80 and 0.25 mg of Al³+ as AlPO4 in 10 mM histidine buffered saline at pH 6.0. Trumenba is administered as a three dose series (0.5 mL each) according to a 0-, 2-, and 6-month schedule.

Locations

Country Name City State
United States UCSF Benioff Children's Hospital Oakland Oakland California
United States University of Massachusetts Medical School Worcester Massachusetts

Sponsors (2)

Lead Sponsor Collaborator
UCSF Benioff Children's Hospital Oakland University of Massachusetts, Worcester

Country where clinical trial is conducted

United States, 

References & Publications (1)

Lujan E, Partridge E, Giuntini S, Ram S, Granoff DM. Breadth and Duration of Meningococcal Serum Bactericidal Activity in Health Care Workers and Microbiologists Immunized with the MenB-FHbp Vaccine. Clin Vaccine Immunol. 2017 Aug 4;24(8). pii: e00121-17. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Breadth of Protective Activity of Serum Anti-FHbp Antibody Responses of Adults Immunized With Trumenba Vaccine as Assessed by Serum Bactericidal Titers Determine the percentage of subjects achieving serum bactericidal titers of 1:4 or greater in serum obtained 1 month after doses 2 and 3 as measured against a panel of 15 genetically diverse meningococcal strains. 18 months
Secondary Antibody Repertoire to FHbp Determine the percentage of recombinant anti-FHbp Fabs isolated from B cells of each subject that react with 3 FHbp amino acid sequence variants representative of FHbp variant groups 1, 2 and 3 1 year
See also
  Status Clinical Trial Phase
Completed NCT00774384 - Regulation of Mucosal Immune Response to Systemic MenB Vaccine Phase 2
Completed NCT00450632 - Creation of a Biotheque of Patients of Seine-Maritime With Meningococcal Infection N/A
Completed NCT00874549 - Exploratory Trial to Evaluate the Safety and Immunogenicity of Menactra® and Menomune® Vaccines in Subjects ≥ 56 Years Phase 1/Phase 2
Completed NCT00850603 - Safety and Immunogenicity of Intradermal Versus Subcutaneous Doses of Menomune® Phase 4
Completed NCT02591290 - Immunogenicity and Safety of Two-Dose Series of Menactra® in Japanese Healthy Adult Subjects Phase 4
Completed NCT03378258 - Petechiae In Children (PIC) Study: Defining A Clinical Decision Rule for The Management Of Fever and Non-Blanching Rashes In Children Including The Role Of Point Of Care Testing For Procalcitonin & Neisseria Meningitidis DNA.
Completed NCT01482052 - Safety Study of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine for Meningitis Phase 1
Completed NCT01239043 - Antibody Persistence and Response to Re-vaccination With Either Menactra® or Menomune® 3 Years After Initial Vaccination Phase 2
Completed NCT01732627 - Study of a Quadrivalent Meningococcal Conjugate Vaccine in Subjects Aged 56 and Older Phase 2
Not yet recruiting NCT05212935 - A Surveillance Study on Timing and Coverage Of Rotavirus and MenB Vaccine Co-administration in Campania Region, Italy
Completed NCT00474487 - A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Healthy Adults Phase 3
Completed NCT02041663 - Septic cArdiac Deficiency and MenIngococcal seveRe Sepsis N/A
Completed NCT03205358 - Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Toddlers Phase 2
Completed NCT00616421 - Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children Phase 3
Completed NCT00450437 - A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults Phase 3
Completed NCT03798574 - The Long-term Impact of Invasive Meningococcal Disease in Australian Adolescents and Young Adults
Completed NCT02640404 - Safety of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine in Healthy Subjects in Vietnam Phase 2
Recruiting NCT05981599 - Epidemiological, Clinical and Biological Caracteristics of Patients Presenting With Invasive Meningococcal Disease
Completed NCT02500511 - Persistence of Protective Antibody Titers 12-24 Months After NmVac4-A/C/Y/W-135-DT Vaccination: Follow Up Study N/A
Completed NCT02199691 - Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents Phase 2